Cybin

Last updated

Cybin IRL
Industry Pharmaceutical; Psychedelic medicine
Founded2019;6 years ago (2019)
Headquarters
Toronto
,
Canada
Website cybin.com

Cybin IRL is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines. [1] [2] [3]

Contents

The company's drug candidates include psilocybin (CYB001), [4] CYB002 (discontinued), [5] CYB003 (deuterated psilocin), [6] [7] [8] [9] CYB004 (deuterated dimethyltryptamine (DMT)), [10] CYB005 (deuterated phenethylamine derivative), [11] [12] [13] and CYB006. [14] [15] Another drug that the company has developed is CYB210010 (2C-T-TFM). [16] [17] [18]

As of January 2025, CYB003 is in phase 3 clinical trials. [6] [7] The drug is one of the only other psychedelics besides Compass Pathways's COMP360 (psilocybin) to have reached this late stage of clinical development. [19] [20]

In 2020, Cybin acquired psychedelic pharmaceutical company Adelia Therapeutics. [21]

See also

References

  1. ↑ Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. (May 2021). "The Therapeutic Potential of Psilocybin". Molecules. 26 (10): 2948. doi: 10.3390/molecules26102948 . PMC   8156539 . PMID   34063505.
  2. ↑ Aday JS, Barnett BS, Grossman D, Murnane KS, Nichols CD, Hendricks PS (September 2023). "Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry". Psychedelic Medicine. 1 (3): 150–165. doi:10.1089/psymed.2023.0013. PMC   11661494 . PMID   40046566. Cybin is currently launching a pilot study of a psilocybin analogue that may produce psychoactive effects for only 4 hours.
  3. ↑ Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST (December 2023). "Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders". Drug Discovery Today. 28 (12) 103818. doi:10.1016/j.drudis.2023.103818. PMID   37925136.
  4. ↑ "Psilocybin - Cybin - AdisInsight". adisinsight.springer.com.
  5. ↑ "Delving into the Latest Updates on CYB-002 with Synapse". Synapse. 23 January 2025. Retrieved 31 January 2025.
  6. 1 2 "CYB 003 - AdisInsight". adisinsight.springer.com.
  7. 1 2 "Delving into the Latest Updates on CYB-003 with Synapse". synapse.patsnap.com.
  8. ↑ Palfreyman M, Krakowsky J, Morgan M, Canal C, Pathare P, Avery K, et al. (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P271-P540". Neuropsychopharmacology. 47 (Suppl 1): 220–370. doi:10.1038/s41386-022-01485-0. PMC   9714399 . PMID   36456694.
  9. ↑ Inamdar A, Morgan M, Krakowsky J, Reichelt A, Canal C, Mueller T, et al. (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P271-P540". Neuropsychopharmacology. 47 (Suppl 1): 220–370. doi:10.1038/s41386-022-01485-0. PMC   9714399 . PMID   36456694.
  10. ↑ "CYB 004 - AdisInsight". adisinsight.springer.com.
  11. ↑ "CYB 005 - AdisInsight". adisinsight.springer.com.
  12. ↑ "Delving into the Latest Updates on CYB-005 with Synapse". synapse.patsnap.com.
  13. ↑ "| BioWorld". www.bioworld.com.
  14. ↑ Alpha P (29 June 2021). "Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement". Psychedelic Alpha. Retrieved 31 January 2025.
  15. ↑ "Development Pipeline". Cybin.
  16. ↑ Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, et al. (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". Journal of Medicinal Chemistry. 67 (8): 6144–6188. doi:10.1021/acs.jmedchem.3c01961. PMID   38593423.
  17. ↑ Palfreyman M, Varty G, Canal C, Hartsel J, Tyagi R, Avery K, et al. (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P405. Discovery and Preclinical Characterization of the Phenylalkylamine, CYB210010, a Potent and Long-Acting Serotonin 5-HT2A Receptor Agonist". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (299–299. doi:10.1038/s41386-023-01756-4. PMC   10729596 . PMID   38040810.
  18. ↑ WO 2023156450,Nivorozhkin A, JA Hartsel, Canal CE, Salituro FG, Mueller TA, Greene BJ, Belser A, Avery KL, Reichelt AC, Varty GB, Palfreyman M,"Therapeutic phenethylamine compositions and methods of use",published 24 August 2023, assigned to Cybin Irl Limited
  19. ↑ Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?". Nature Biotechnology. 42 (6): 827–830. doi:10.1038/s41587-024-02285-1. PMID   38831049.
  20. ↑ Haichin M (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
  21. ↑ Cybin Inc. (14 December 2020). "CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings". GlobeNewswire News Room (Press release). Retrieved 6 February 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.